More recently, in a much larger study using tissue microarray (TMA) strategies, Blanchard et al. [73], showed that only a small percentage of ER+ breast cancers were positive for claudin 1 whereas a significantly higher level of ER− tumors exhibited claudin 1 positivity. Here, CLDN1 is linked to breast carcinoma.